Replies to post #1041 on Bristol Myers Squibb (BMY)

[DewDiligence]

BMY will_advance Deucravacitinib to_phase-3_in lupus, based on phase-2 data presented at EULAR:

https://www.businesswire.com/news/home/20220531005751/en

Deucravacitinib is under FDA and EMA review in psoriasis; the PDUFA date is 9/10/22 (#msg-166931026).